The novel finding that TXNIP expression is low in ATC is consistent with the observed FDG uptake on PET/CT in patients with ATC, supporting a critical role for TXNIP as a metabolic regulator in thyroid cancer progression. The gene discussed is TXNIP; the disease is thyroid cancer.